EGM
YMAB

Engineers Gate Manager’s Y-mAbs Therapeutics YMAB Stock Holding History

Engineers Gate Manager’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,386
Closed -$214K – 2634
2024
Q4 		$214K Buy
+27,386
New +$334K ﹤0.01% 1863
2023
Q3 		– Sell
-14,100
Closed -$95.7K – 2126
2023
Q2 		$95.7K Buy
+14,100
New +$106K ﹤0.01% 1575
2021
Q2 		– Sell
-17,700
Closed -$535K – 2080
2021
Q1 		$535K Buy
+17,700
New +$726K 0.03% 949

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Engineers Gate Manager's YMAB Position: Q1 2025 in Review

Engineers Gate Manager sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 27,386 shares — an estimated $214K sold.

Engineers Gate Manager first reported a position in YMAB in Q1 2021 and held it in 3 quarters. The position peaked at $535K in Q1 2021. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Engineers Gate Manager reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Engineers Gate Manager sold 27,386 Y-mAbs Therapeutics shares in Q1 2025, an estimated $214K.
  • Engineers Gate Manager first reported a position in Y-mAbs Therapeutics in Q1 2021 and held it in 3 quarters.
  • Engineers Gate Manager's Y-mAbs Therapeutics position peaked at $535K in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Engineers Gate Manager's 13F filing for Q1 2025, filed 15 May 2025.